在患有异常性肺纤维化患者的肺切除中使用外科尼特达尼布
Ryusuke Sumiya1,2, Takamitsu Banno1, Hiroyasu Ueno1
1Department of General Thoracic Surgery, Juntendo University Nerima Hospital, Tokyo 177-8521, Japan.
Molecular and clinical oncology
|May 5, 2025
概括
尼丁达尼布是一种抗纤维化药物,在为间歇性肺炎进行肺切除的患者中,证明了术后的安全性. 该研究发现,由于副作用,没有人取消手术,30天死亡率为0%.
科学领域:
- 肺部病理学 肺部病理学
- 胸部外科手术 胸部外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 丁丁达尼布是一种抗纤维性药物,已知可以减缓肺功能下降,并预防间歇性肺炎的急性恶化.
- 在接受肺切除的患者中,宁泰达尼布的外科安全性和疗效仍未得到充分研究.
研究的目的:
- 评估宁泰达尼布在接受肺切除手术的间歇性肺炎患者的安全性和有效性.
- 评估手术前任他迪尼布给药对手术结果和术后并发症的影响.
主要方法:
- 一项对12名患有异常性肺纤维化和肺癌的患者 (10名男性,2名女性) 的回顾性研究,这些患者接受了肺切除术 (双切除术,叶切除术,细分切除术,切除术).
- 在手术前的14至43天内,Nintedanib在手术前进行了治疗.
- 分析了手术结果,包括术后并发症和30天死亡率.
主要成果:
- 在这12名患者中,没有一个因忍丹尼布副作用而取消或推迟手术.
- 手术后的并发症包括长时间的空气泄漏 (n=3),手术部位感染 (n=2),胸腔 (n=1),心力衰竭 (n=1) 和多 (n=1).
- 30天死亡率为0%,没有观察到间歇性肺炎的急性恶化.
结论:
- 在经过肺切除的间歇性肺炎患者中,经过外科手术的宁泰达尼布似乎是安全的.
- 需要进一步的前性研究和更大的队列来证实这些发现并优化治疗方案.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
Endoscopic Studies I: Bronchoscopy and Thoracoscopy
140
Endoscopy is a non-surgical medical technique used to examine a person's internal organs and vessels. This lesson will focus on two types of endoscopic studies: bronchoscopy and thoracoscopy.
Bronchoscopy
Description
Bronchoscopy is a procedure that involves direct visualization of the larynx, trachea, and bronchi for diagnostic and therapeutic purposes. A flexible fiber optic or rigid bronchoscope is used to carry out the procedure. The fiber-optic bronchoscope is more frequently used due...
Bronchoscopy
Description
Bronchoscopy is a procedure that involves direct visualization of the larynx, trachea, and bronchi for diagnostic and therapeutic purposes. A flexible fiber optic or rigid bronchoscope is used to carry out the procedure. The fiber-optic bronchoscope is more frequently used due...
140
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
82
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
82
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
89
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
89


